NVO NOVO NORDISK A S

NYSE novonordisk.com


$ 47.93 $ 0.24 (0.5 %)    

Thursday, 06-Nov-2025 12:04:11 EST
QQQ $ 611.63 $ -10.16 (-1.63 %)
DIA $ 468.13 $ -3.88 (-0.82 %)
SPY $ 669.78 $ -6.70 (-0.99 %)
TLT $ 89.82 $ 0.26 (0.28 %)
GLD $ 366.41 $ -0.74 (-0.2 %)
$ 48.46
$ 47.68
$ 47.97 x 633
$ 48.00 x 320
$ 46.80 - $ 48.48
$ 44.55 - $ 109.43
37,996,646
na
218.55B
$ 0.75
$ 15.59
TBD
na
na ($ 0.04)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

https://www.youtube.com/watch?v=GFGmukrxZ7Y

Core News & Articles

https://www.youtube.com/watch?v=GFGmukrxZ7Y

 higher-dose-of-wegovy-demonstrates-weight-loss-and-cardiovascular-benefits

Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for n...

 pfizer-to-raise-metsera-bid-after-court-denies-attempt-to-block-rival-deal

Delaware court denies Pfizer bid to block Metsera's Novo Nordisk deal as FTC flags antitrust risks and Pfizer prepares a hi...

Core News & Articles

https://www.ft.com/content/52216b29-9f22-4338-85a7-eacfc33103a1

 trump-administrations-weight-loss-drug-deal-is-sending-this-novo-nordisk-rival-surging-momentum-score-spikes

A leading pharmaceutical stock that goes head-to-head against Novo Nordisk A/S is surging amid a potential deal with the Trump ...

Core News & Articles

-Reuters Citing FTC Letter To Metsera

Core News & Articles

-Reuters Citing Metsera Letter To Court

Core News & Articles

-Reuters Citing Letter To Court

Core News & Articles

https://x.com/jenniferjjacobs/status/1986132394470985850?s=46&t=dtUiyC3dUs5yGRgT9qYHWg

 novo-nordisk-q3-2025-earnings-call-transcript

Novo Nordisk reported third-quarter financial results on Wednesday. The transcript from the company's earnings call has bee...

 druckenmillers-viking-trade-just-hit-a-golden-cross--and-a-sweet-36-gain

Stanley Druckenmiller's firm bought Viking Therapeutics stock (VKTX) during Q2 at $25.33. Now up 36%, VKTX shows a Golden C...

 ozempic-maker-novo-nordisk-trims-growth-outlook-for-obesity-drugs

Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook.

 novo-nordisk-ceo-says-company-expanding-telehealth-for-obesity-care-confident-in-pipeline-but-seeking-more-candidates-cfo-notes-growth-deceleration-toward-year-end

-Reuters

 novo-nordisk-fy2025-sales-growth-is-expected-to-be-8-11-at-cer

Novo Nordisk (NYSE:NVO) FY2025 Sales growth is expected to be 8-11% at CER

 novo-nordisk-q3-adj-eps-103-beats-077-estimate-sales-11745b-miss-11880b-estimate

Novo Nordisk (NYSE:NVO) reported quarterly earnings of $1.03 per share which beat the analyst consensus estimate of $0.77 by 33...

 novo-pfizer-are-battling-to-buy-the-future-of-weight-loss--but-viking-already-owns-it

Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nor...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION